Skip to content
Review

AEG-1/MTDH: A central regulator of tumor progression, metabolic adaptation, and therapeutic resistance in gliomas.

Aug 2026 · Tissue & Cell · Vol 104 Pt 1, pp. 103839 · 0 citations · 114 references
Medicine

TL;DR

Gen silencing studies demonstrate that AEG-1 knockdown reduces proliferation, promotes apoptosis, and enhances sensitivity to chemotherapeutic agents such as cisplatin, doxorubicin, and temozolomide, and support its potential as a target for combinatorial therapeutic strategies to improve outcomes in aggressive brain and pediatric tumors.

Abstract

Astrocyte-elevated gene-1 (AEG-1), also known as metadherin (MTDH), is a pleiotropic oncogene critically involved in the onset and development of glioblastoma (GBM), other malignant gliomas, and neuroblastoma. Its expression is upregulated under hypoxic conditions and during glucose deprivation, enabling tumor cells to survive severe metabolic stress while sustaining glycolysis. AEG-1 also has emerged as a reliable prognostic and diagnostic biomarker in gliomas, astrocytomas, oligodendrogliomas, and neuroblastomas. High AEG-1 expression correlates with advanced tumor grade, rapid disease progression, metastasis, and poor overall survival, independent of conventional clinical variables. Co-expression of AEG-1 with MDM2 further predicts higher recurrence and reduced survival, highlighting its value in patient stratification and clinical decision-making. Beyond its prognostic relevance, AEG-1 is a promising therapeutic target. Importantly, gene silencing studies demonstrate that AEG-1 knockdown reduces proliferation, promotes apoptosis, and enhances sensitivity to chemotherapeutic agents such as cisplatin, doxorubicin, and temozolomide. Mechanistically, inhibition of AEG-1 disrupts survival pathways including PI3K/Akt, impairs DNA repair, and attenuates immunosuppressive tumor microenvironments. Small-molecule inhibitors, such as DYT-40, synergistically target AEG-1 and NF-κB, reducing tumor growth and invasion in glioblastoma models. Moreover, AEG-1 suppression sensitizes cancer cells to radiotherapy by impairing homologous recombination repair and enhancing DNA damage-induced apoptosis. Collectively, these findings underscore AEG-1 as a central regulator of tumor progression, chemoresistance, and radioresistance, and support its potential as a target for combinatorial therapeutic strategies to improve outcomes in aggressive brain and pediatric tumors.

View source

Similar papers

Review Sep 2026

Temozolomide resistance in glioblastoma: Multidimensional networks, core signaling hubs, and targeted therapeutic strategies.

This review systematically illustrates the regulatory networks governing GBM pathogenesis and TMZ resistance, and dissects signaling cascades of distinct resistance mechanisms and crosstalk between core signaling axes, and identifies key regulatory molecules and druggable targets for each resistance phenotype.

Ying Qin, Yu-Fang Zhao, Bo-Wen Li et al. · 0 citations
Open access Aug 2026

34 Therapeutic Targeting of the SLC7A11-GCLM-GPX4 Axis Sensitizes Glioblastoma to Ferroptosis and Associates with Poor Survival

The GPX-4/GCLM axis, which balances redox, is highly expressed and crucial for GBM cell survival and aggressive biological behavior and may be a valuable adjunct to diagnosis, as demonstrated by RSL3, FIN56, and BSO.

M. Behera, S. Purkait, Amit Ghosh et al. · 0 citations
Review Open access Sep 2026

Redox Regulation in Glioblastoma: Mechanisms, Biomarkers, and Therapeutic Implications

The potential of understanding oxidative stress mechanisms to develop therapeutic strategies that target redox balance and homeostasis, aiming to overcome resistance and improve survival outcomes for glioblastoma patients is discussed.

Salma Lamrabet, A. Houssaini, Sanae Bennis et al. · 0 citations
Open access Sep 2026

Pan-Cancer Landscape of the Novel Oxygen Sensor ADO and Its Potential Role in Hepatocellular Carcinoma

Background Hypoxia is a key driver of tumor progression across cancers, yet oxygen-sensing mechanisms beyond HIFs remain underexplored. 2-Aminoethanethiol dioxygenase (ADO) has recently been identified as an oxygen sensor, but its role in malignancy is poorly defined. We conducted a pan-cancer analysis of ADO with a sp...

Jie Huang, Ying Xu, Yu-Qing Wang et al. · 0 citations
Review Open access Sep 2026

uPAR-directed immunotherapies in solid tumors: current advances and future perspectives

This review provides a comprehensive overview of the principal uPAR-directed immunotherapeutic strategies currently under investigation, including chimeric antigen receptor (CAR) T-cell therapies, multi-epitope vaccines, monoclonal antibodies, and radioligand-based approaches.

F. Napolitano, N. Montuori · 0 citations
2026

Deciphering the oncogenic role of RRM2 in Glioblastoma multiforme and its modulation by plant derived compounds

Data make RRM2 an attractive therapeutic candidate in GBM and suggest some phytochemicals as potential inhibitors, which provide a logical basis for further experimental validation and creation of new, plant-tailored therapeutic interventions to manage GBM.

S. Singh, Pardeep Yadav, S. K. Jha · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.